Comparative Pharmacology
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE ALLERGY versus ZYRTEC ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CETIRIZINE HYDROCHLORIDE ALLERGY versus ZYRTEC ALLERGY.
CETIRIZINE HYDROCHLORIDE ALLERGY vs ZYRTEC ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine hydrochloride is a second-generation histamine H1-receptor antagonist. It acts by selectively and reversibly blocking histamine H1 receptors on effector cells (e.g., smooth muscle, endothelial cells, mucous glands), thereby inhibiting histamine-mediated allergic responses such as vasodilation, increased vascular permeability, bronchoconstriction, and itching. It does not prevent histamine release but antagonizes its effects.
Selective peripheral histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
5-10 mg orally once daily; maximum 10 mg/day.
5–10 mg orally once daily; maximum dose 10 mg/day.
None Documented
None Documented
Terminal elimination half-life: approximately 8-11 hours in healthy adults; increases to ~18-20 hours in elderly (due to decreased renal function); prolonged in renal impairment (CrCl <31 mL/min: up to 20-30 hours)
Terminal elimination half-life is approximately 8.3 hours (range 6–10 hours) in healthy adults, prolonged to 20–25 hours in patients with renal impairment (CrCl < 40 mL/min). No significant difference in elderly vs. young adults with normal renal function.
Renal: approximately 70% (60% as unchanged drug, 10% as metabolites); Fecal: approximately 10%; Biliary: negligible
Renal excretion of unchanged drug accounts for approximately 70% of elimination; approximately 10% is excreted in feces via biliary route. Total renal excretion includes both parent drug and metabolites, with cetirizine largely unchanged.
Category A/B
Category C
Antihistamine
Antihistamine